Legal Representation
Attorney
Patrick J. Jennings
USPTO Deadlines
Next Deadline
676 days remaining
Section 8 & 9 Renewal Due (Principal Register) (Based on registration date 20171031)
Due Date
October 31, 2027
Grace Period Ends
April 30, 2028
Application History
40 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 25, 2024 | NA85 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | Loading... |
| Oct 25, 2024 | C15P | O | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | Loading... |
| Oct 25, 2024 | EROP | I | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | Loading... |
| Oct 23, 2024 | PR23 | O | POST REGISTRATION ACTION MAILED - SEC. 8 & 15 | Loading... |
| Oct 23, 2024 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Apr 30, 2024 | E815 | I | TEAS SECTION 8 & 15 RECEIVED | Loading... |
| Oct 31, 2022 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Oct 31, 2017 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Aug 15, 2017 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 15, 2017 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 26, 2017 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 6, 2017 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 8, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 8, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 2, 2017 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 8, 2017 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| May 8, 2017 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| May 8, 2017 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| May 8, 2017 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Apr 10, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 10, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 10, 2017 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Nov 25, 2016 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Nov 25, 2016 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Nov 25, 2016 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Oct 24, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 24, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 24, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 20, 2016 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Oct 20, 2016 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Aug 3, 2016 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Jul 6, 2016 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 6, 2016 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 6, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 27, 2016 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 23, 2016 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | Loading... |
| Mar 23, 2016 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Mar 22, 2016 | MPMK | E | NOTICE OF PSEUDO MARK E-MAILED | Loading... |
| Mar 21, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 19, 2016 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products [ in the nature of chemicals ] for cancer treatment, oncology and immunotherapy; [ sanitary preparations for medical purposes; ] pharmaceutical products for human medicine for cancer treatment, oncology and immunotherapy; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy [ for auto immune diseases and biological tissue grafts or skin grafts; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Substances for medicinal use, namely, synthetic peptides for cancer treatment, oncology and immunotherapy, adjuvants for medical purposes, stem cells for medical purposes; Vaccines for treating cancer; vaccines; Substances for medicinal use, namely, serums for cancer treatment, oncology and immunotherapy, monoclonal antibodies for cancers, auto immune diseases and biological tissue grafts or skin grafts; Pharmaceutical products, namely, targeted therapies for cancers, auto immune diseases and biological tissue grafts or skin grafts ]
Class 042
[ Scientific and technological services, namely, research and design services in the fields of cancer treatment, oncology, immunotherapy; design and development of software and databases; medical research; biological and biotechnology research; pharmaceutical research; conducting clinical studies for others ]
Class 044
[ Medical services ]
Additional Information
Pseudo Mark
ORPHAN SYNERGY EUROPE IMMUNE THERAPEUTICS
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"IMMUNOTHERAPEUTICS"